14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Mar 03, 2026
VTYX vs MNMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Mar 03, 2026, Ventyx Biosciences, Inc. (VTYX) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs MNMD. Trailing 12-month operating profitability (VTYX 0.0% vs MNMD 0.0%) and valuation multiples (VTYX N/M vs MNMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VTYX vs MNMD Key Questions & Quantitative Answers
As of Mar 03, 2026, Ventyx Biosciences, Inc. (VTYX) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas MNMD carries 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
MNMD leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MNMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus N/A for MNMD. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MNMD.
VTYX and MNMD trade at balanced relative valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus MNMD (-85.6% ROE) capital efficiency.
In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Mar 03, 2026. For educational research only; not investment advice.